MHRA — authorised 25 April 2022
- Marketing authorisation holder: BIOHAVEN PHARMACEUTICAL IRELAND DAC
- Status: approved
🇬🇧 Nurtec Odt in United Kingdom
MHRA authorised Nurtec Odt on 25 April 2022 · NICE has issued 2 UK HTA decisions
Marketing authorisation
Health technology assessment
2 decisions from NICE for Nurtec Odt in United Kingdom.
NICE TA919 — ✓ Recommended
- Indication assessed: treating migraine
NICE recommended Nurtec Odt for treating migraine in the United Kingdom. This decision was made without a specific cost basis reported. There are no restrictions or conditions associated with this recommendation.
NICE TA906 — ✓ Recommended
- Indication assessed: preventing migraine
NICE recommended Nurtec Odt for preventing migraine attacks in adults. This decision was made based on a commercial arrangement. No restriction or condition was placed on the use of Nurtec Odt.
Nurtec Odt in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United Kingdom
Frequently asked questions
Is Nurtec Odt approved in United Kingdom?
Yes. MHRA authorised it on 25 April 2022.
Who is the marketing authorisation holder for Nurtec Odt in United Kingdom?
BIOHAVEN PHARMACEUTICAL IRELAND DAC holds the UK marketing authorisation.
Has Nurtec Odt been assessed by UK health technology agencies?
Yes — 2 UK HTA decisions on record from NICE.